Macrogenics Inc (NAS:MGNX)
$ 4.36 0.25 (6.07%) Market Cap: 273.08 Mil Enterprise Value: 107.83 Mil PE Ratio: 0 PB Ratio: 2.57 GF Score: 60/100

MacroGenics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 30, 2021 / 04:40PM GMT
Release Date Price: $20.94 (+2.20%)
Brian Cheng
Cantor Fitzgerald - Analyst

Good afternoon. Thank you for joining us today for another session at our annual Global Healthcare Conference. I'm Brian Cheng. I'm the Senior Biotech Analyst here at Cantor. It's my pleasure to introduce to you next the management team from MacroGenics. Joining us is their President and CEO, Scott Koenig.

Scott, welcome, and thanks for joining us today.

Scott Koenig
MacroGenics, Inc - President and CEO

Thank you very much, Brian. And thank you for the opportunity to present at the Cantor Conference. I will be making forward-looking statements during my presentation, so please refer to our SEC filings to understand the risks in investing in MacroGenics.

2021 was a year of significant advancement for MacroGenics. We launched MARGENZA, our first in-house developed proprietary product, with our partner EVERSANA in March. We significantly advanced our B7-H3 portfolio and continue to demonstrate the value of our technology platforms, which include our bispecific DART technology, our Fc Optimization

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot